Resumo

AGUDELO-ZAPATA, Yessica; BURGOS-CARDENAS, Álvaro Javier; DIAZ-MARTINEZ, Ángela Johana  e  PINILLA-ROA, Análida Elizabeth. Dipeptidil dipeptidase-IV inhibidors: from the theory to the practice. rev.fac.med. [online]. 2015, vol.63, n.2, pp.259-270. ISSN 0120-0011.  https://doi.org/10.15446/revfacmed.v63n2.48820.

This review of dipeptidyl peptidase-IV inhibitors seeks to encourage the rational use of these drugs in daily practice; this group is a new therapeutic option in monotherapy or combination therapy for the treatment of patients with diabetes mellitus type 2. Sitagliptin, vildagliptin, saxagliptin and linagliptin are available in Colombia. While all gliptins have the same mechanism of action-they increase the average life of glucagon-like peptide-, this review presents the differences among their pharmacological properties, adverse events and safety profile. These drugs are second or third-line for the oral treatment of patients with diabetes mellitus type 2, or first-line in patients intolerant to metformin. They also have some advantages like lower risk of hypoglycemia, neutral effect on weight, safety for the elderly, reduction of glycaemia variability; additionally, they can be used in advanced chronic kidney disease, with or without renal replacement therapy, and in liver failure.

Palavras-chave : Diabetes mellitus; type 2; Dipeptidyl-peptidase IV inhibitors; Incretins.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )